Evolocumab use in clinical practice in Switzerland: final data of the observational HEYMANS cohort study.

ABSTRACT:

Aims

The HEYMANS study observed patients receiving evolocumab as part of routine clinical hyperlipidemia management. It was designed to capture data on clinical parameters relevant to health authorities and physicians.

Methods

This was a European multi-country observational cohort serial chart review study; data on the Swiss cohort are reported here. Patients were prescribed evolocumab as per the Swiss reimbursement criteria in force at the time and were invited chronologically. The study consisted of a 6-month period prior to initiation of evolocumab, a 12-month core observation period (entered by 75 patients, completed by 74 patients), and an 18-month extended observation period (entered by 40 patients, completed by 34 patients). The primary objective was to describe the c

SUBMITTER: Sudano I 

PROVIDER: S-EPMC10771737 | biostudies-literature | 2024 Jan-Dec

REPOSITORIES: biostudies-literature